Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 29, 2009
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
About 30% of cirrhotic patients will develop ascites. Sodium restriction and diuretics are the first step treatment. Total paracentesis is used in patients with cirrhosis and tense ascites. Paracentesis alone was found to induce a decrease in effective arterial blood volume. This circulatory dysfunction may induce inhospital complications such as impaired renal function or hyponatremia and is associated with a significant reduction in long term survival. Intravenous albumin administration after paracentesis has been shown to prevent the post paracentesis decrease in arterial blood volume. P...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient aged 18 years old and more with cirrhosis and refractory ascites define by the international ascites club.
- • Vital status non engaged in the 2 months
- Exclusion Criteria:
- • cardiovascular disease : previous or actual angina pectoralis, myocardial infarction, heart failure, rhythm or conduction disorders, repolarisation abnormality on ECG
- • respiratory disease: previous or actual chronic pulmonary insufficiency, asthma
- • uncontrolled hypertension
- • acute portal vein thrombosis (less then 3 months) or currently treated.
- • chronic renal insufficiency (creatin \> 15 mg/L)
- • severe hepatic encephalopathy
- • Alcoholic hepatitis or gastrointestinal bleeding in the last 3 months
- • hepatocellular carcinoma
- • severe illness with life threatening
- • pregnant or breastfeeding women
Trial Officials
Nicolas Carbonell, MD
Principal Investigator
Hôpital Saint Antoine
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
